Noxopharm (ASX: NOX) announces that Dr Graham Kelly will assume the duties of interim CEO following the departure of former CEO, Dr Greg van Wyk.
While the Board understands that a dual CEO/Chairman is not optimal, it proposes to appoint an Australian-based senior executive with a strong financial and business background to assist Dr Kelly in what is anticipated to be a period of strong corporate and business growth.
For more information, please download the attached PDF.
Download this document
